Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 327

1.

New HIV-1 circulating recombinant form 94: from phylogenetic detection of a large transmission cluster to prevention in the age of geosocial-networking apps in France, 2013 to 2017.

Wirden M, De Oliveira F, Bouvier-Alias M, Lambert-Niclot S, Chaix ML, Raymond S, Si-Mohammed A, Alloui C, André-Garnier E, Bellecave P, Malve B, Mirand A, Pallier C, Poveda JD, Rabenja T, Schneider V, Signori-Schmuck A, Stefic K, Calvez V, Descamps D, Plantier JC, Marcelin AG, Visseaux B, On Behalf Of The French National Agency For Research On Aids And Viral Hepatitis Anrs Ac Study Group.

Euro Surveill. 2019 Sep;24(39). doi: 10.2807/1560-7917.ES.2019.24.39.1800658.

2.

Prevalence of hypertension and cardiovascular risk factors among long-term AIDS survivors: A report from the field.

Pierre S, Seo G, Rivera VR, Walsh KF, Victor JJ, Charles B, Julmiste G, Dumont E, Apollon A, Cadet M, Saint-Vil A, Marcelin A, Severe P, Lee MH, Kingery J, Koenig S, Fitzgerald D, Pape J, McNairy ML.

J Clin Hypertens (Greenwich). 2019 Aug 26. doi: 10.1111/jch.13663. [Epub ahead of print]

3.

Second-line antiretroviral therapy failure and characterization of HIV-1 drug resistance patterns in children in Mali.

Sylla M, Dolo O, Maiga AI, Traore FT, Coulibaly YA, Togo J, Fofana DB, Dicko-Traore F, Doumbia S, Orsega S, Diallo S, Murphy RL, Calvez V, Marcelin AG.

Arch Pediatr. 2019 Jul;26(5):254-258. doi: 10.1016/j.arcped.2019.06.002. Epub 2019 Jul 12.

PMID:
31307909
4.

Antiretroviral drug reduction in highly experienced HIV-infected patients receiving a multidrug regimen: the ECOVIR study.

Valantin MA, Durand L, Wirden M, Assoumou L, Caby F, Soulié C, Nguyen TT, Tubiana R, Kirstetter M, Junot H, Marcelin AG, Peytavin G, Tilleul P, Katlama C.

J Antimicrob Chemother. 2019 Sep 1;74(9):2716-2722. doi: 10.1093/jac/dkz255.

PMID:
31273376
5.

Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study.

Katlama C, Assoumou L, Valantin MA, Soulié C, Martinez E, Béniguel L, Bouchaud O, Raffi F, Molina JM, Fellahi S, Peytavin G, Marcelin AG, Kolta S, Capeau J, Gibowski S, Cardon F, Reynes J, Costagliola D; members of the ANRS 163 ETRAL study .

J Antimicrob Chemother. 2019 Sep 1;74(9):2742-2751. doi: 10.1093/jac/dkz224.

PMID:
31269208
6.

Uncommon Detection of Mixed HCV Genotype Infections in Recently Infected Men Who Have Sex with Men.

Nguyen T, Delaugerre C, Valantin MA, Amiel C, Netzer E, L'Yavanc T, Ohayon M, Israel G, Valin N, Day N, Kreplak G, Pialoux G, Calvez V, Molina JM, Marcelin AG, Todesco E.

Int J Antimicrob Agents. 2019 Oct;54(4):513-517. doi: 10.1016/j.ijantimicag.2019.06.001. Epub 2019 Jun 11.

PMID:
31195120
7.

Shared HCV Transmission Networks Among HIV-1-Positive and HIV-1-Negative Men Having Sex With Men by Ultradeep Sequencing.

Nguyen T, Delaugerre C, Valantin MA, Amiel C, Netzer E, Lʼyavanc T, Ohayon M, Valin N, Day N, Kreplak G, Pialoux G, Calvez V, Molina JM, Marcelin AG, Todesco E.

J Acquir Immune Defic Syndr. 2019 Sep 1;82(1):105-110. doi: 10.1097/QAI.0000000000002099.

PMID:
31169768
8.

Low hepatitis D seroprevalence in blood donors of Bamako, Mali.

Marino Q, Cisse M, Gerber A, Dolo O, Sayon S, Ba A, Brichler S, Tata Traore F, Gordien E, Togo J, Calvez V, Marcelin AG, Issiaka Maiga A, Todesco E.

Infect Dis (Lond). 2019 Aug;51(8):622-624. doi: 10.1080/23744235.2019.1620963. Epub 2019 Jun 5. No abstract available.

PMID:
31165648
9.

INSTI-Based Triple Regimens in Treatment-Naïve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow Levels.

Lambert-Niclot S, Boyd A, Fofana D, Valin N, Wirden M, Meynard JL, Palich R, Agher R, Valantin MA, Calvez V, Katlama C, Girard PM, Marcelin AG, Morand-Joubert L.

Open Forum Infect Dis. 2019 Apr 10;6(5):ofz177. doi: 10.1093/ofid/ofz177. eCollection 2019 May.

10.

New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations.

Castain L, Perrier M, Charpentier C, Palich R, Desire N, Wirden M, Descamps D, Sayon S, Landman R, Valantin MA, Joly V, Peytavin G, Yazdanpanah Y, Katlama C, Calvez V, Marcelin AG, Todesco E.

J Antimicrob Chemother. 2019 Jul 1;74(7):2019-2023. doi: 10.1093/jac/dkz151.

PMID:
31050739
11.

Routine screening for HIV, hepatitis B virus and hepatitis C virus in individuals undergoing oral and maxillofacial surgery.

Assoumou L, Thormann F, Soulié C, Caby F, Dudoit Y, Marcelin AG, Goudot P, Blanc C, Coriat P, Katlama C, Costagliola D, Pourcher V.

HIV Med. 2019 May;20(5):353-358. doi: 10.1111/hiv.12732. Epub 2019 Mar 29.

PMID:
30924598
12.

Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study.

Lê MP, Valantin MA, Assoumou L, Soulie C, Le Mestre S, Weiss L, Yazdanpanah Y, Molina JM, Bouchaud O, Raffi F, Reynes J, Calvez V, Marcelin AG, Costagliola D, Katlama C, Peytavin G; ANRS-163 ETRAL study group.

Pharmacotherapy. 2019 Apr;39(4):514-520. doi: 10.1002/phar.2242. Epub 2019 Apr 1.

PMID:
30815916
13.

Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients.

Marcelin AG, Grude M, Charpentier C, Bellecave P, Le Guen L, Pallier C, Raymond S, Mirand A, Bocket L, Fofana DB, Delaugerre C, Nguyen T, Montès B, Jeulin H, Mourez T, Fafi-Kremer S, Amiel C, Roussel C, Dina J, Trabaud MA, Le Guillou-Guillemette H, Vallet S, Signori-Schmuck A, Maillard A, Ferre V, Descamps D, Calvez V, Flandre P; ANRS AC43 Resistance Group.

J Antimicrob Chemother. 2019 May 1;74(5):1368-1375. doi: 10.1093/jac/dkz021.

PMID:
30789205
14.

HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen.

Perrier M, Castain L, Regad L, Todesco E, Landman R, Visseaux B, Yazdanpanah Y, Rodriguez C, Joly V, Calvez V, Marcelin AG, Descamps D, Charpentier C.

J Antimicrob Chemother. 2019 Jun 1;74(6):1679-1692. doi: 10.1093/jac/dkz043.

PMID:
30768160
15.

High clustering of acute HCV infections and high rate of associated STIs among Parisian HIV-positive male patients.

Todesco E, Day N, Amiel C, Elaerts S, Schneider V, Roudière L, Hué S, Liotier JY, Bottero J, L'Yavanc T, Ohayon M, Gosset D, Thibault V, Surgers L, Chas J, Akhavan S, Velter A, Katlama C, Kreplak G, Marcelin AG, Valantin MA.

Int J Antimicrob Agents. 2019 May;53(5):678-681. doi: 10.1016/j.ijantimicag.2019.02.002. Epub 2019 Feb 8.

16.

Caution is needed in interpreting HIV transmission chains by ultradeep sequencing.

Todesco E, Wirden M, Calin R, Simon A, Sayon S, Barin F, Katlama C, Calvez V, Marcelin AG, Hué S.

AIDS. 2019 Mar 15;33(4):691-699. doi: 10.1097/QAD.0000000000002105.

PMID:
30585843
17.

Characterization update of HIV-1 M subtypes diversity and proposal for subtypes A and D sub-subtypes reclassification.

Désiré N, Cerutti L, Le Hingrat Q, Perrier M, Emler S, Calvez V, Descamps D, Marcelin AG, Hué S, Visseaux B.

Retrovirology. 2018 Dec 22;15(1):80. doi: 10.1186/s12977-018-0461-y.

18.

Evaluation of Two HIV Rapid Diagnostic Tests in a Context of Strains' Genetic Diversity in Mali.

Togo J, Maiga AI, Sylla M, Kone B, Dolo O, Traore FT, Sangare SA, Maiga M, Diallo S, Murphy R, Calvez V, Marcelin AG.

AIDS Res Hum Retroviruses. 2019 Feb;35(2):145-149. doi: 10.1089/AID.2017.0296. Epub 2019 Jan 22.

19.

Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients.

Soulie C, Santoro MM, Charpentier C, Storto A, Paraskevis D, Di Carlo D, Gennari W, Sterrantino G, Zazzi M, Perno CF, Calvez V, Descamps D, Ceccherini-Silberstein F, Marcelin AG.

J Antimicrob Chemother. 2019 Mar 1;74(3):614-617. doi: 10.1093/jac/dky464.

PMID:
30476106
20.

Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART.

Derache A, Iwuji CC, Danaviah S, Giandhari J, Marcelin AG, Calvez V, de Oliveira T, Dabis F, Pillay D, Gupta RK.

J Antimicrob Chemother. 2019 Feb 1;74(2):473-479. doi: 10.1093/jac/dky428.

21.

Impact of Next-generation Sequencing Defined Human Immunodeficiency Virus Pretreatment Drug Resistance on Virological Outcomes in the ANRS 12249 Treatment-as-Prevention Trial.

Derache A, Iwuji CC, Baisley K, Danaviah S, Marcelin AG, Calvez V, de Oliveira T, Dabis F, Porter K, Pillay D.

Clin Infect Dis. 2019 Jul 2;69(2):207-214. doi: 10.1093/cid/ciy881.

22.

Net emergence of substitutions at position 28 in NS5A of hepatitis C virus genotype 4 in patients failing direct-acting antivirals detected by next-generation sequencing.

Nguyen T, Akhavan S, Caby F, Bonyhay L, Larrouy L, Gervais A, Lebray P, Poynard T, Calmus Y, Simon A, Valantin MA, Calvez V, Marcelin AG, Todesco E.

Int J Antimicrob Agents. 2019 Jan;53(1):80-83. doi: 10.1016/j.ijantimicag.2018.09.010. Epub 2018 Sep 17.

PMID:
30236959
23.

Predicting death and lost to follow-up among adults initiating antiretroviral therapy in resource-limited settings: Derivation and external validation of a risk score in Haiti.

McNairy ML, Jannat-Khah D, Pape JW, Marcelin A, Joseph P, Mathon JE, Koenig S, Wells M, Fitzgerald DW, Evans A.

PLoS One. 2018 Aug 29;13(8):e0201945. doi: 10.1371/journal.pone.0201945. eCollection 2018.

24.

New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T).

Pouga L, Santoro MM, Charpentier C, Di Carlo D, Romeo I, Artese A, Alcaro S, Antinori A, Wirden M, Perno CF, Ambrosio FA, Calvez V, Descamps D, Marcelin AG, Ceccherini-Silberstein F, Lambert-Niclot S.

Chem Biol Drug Des. 2019 Jan;93(1):50-59. doi: 10.1111/cbdd.13378. Epub 2018 Nov 27.

PMID:
30103267
25.

Resistance profile and treatment outcomes in HIV-infected children at virological failure in Benin, West Africa.

Fofana DB, d'Almeida M, Lambert-Niclot S, Peytavin G, Girard PM, Lafia B, Zohoun-Guidigbi L, Keke RK, Soulie C, Marcelin AG, Morand-Joubert L.

J Antimicrob Chemother. 2018 Nov 1;73(11):3143-3147. doi: 10.1093/jac/dky300.

PMID:
30060186
26.

Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing.

Nguyen T, Fofana DB, Lê MP, Charpentier C, Peytavin G, Wirden M, Lambert-Niclot S, Desire N, Grude M, Morand-Joubert L, Flandre P, Katlama C, Descamps D, Calvez V, Todesco E, Marcelin AG.

J Antimicrob Chemother. 2018 Sep 1;73(9):2485-2492. doi: 10.1093/jac/dky198.

PMID:
29873733
27.

Evaluation of different analysis pipelines for the detection of HIV-1 minority resistant variants.

Perrier M, Désiré N, Storto A, Todesco E, Rodriguez C, Bertine M, Le Hingrat Q, Visseaux B, Calvez V, Descamps D, Marcelin AG, Charpentier C.

PLoS One. 2018 Jun 1;13(6):e0198334. doi: 10.1371/journal.pone.0198334. eCollection 2018.

28.

Dynamics of drug resistance-associated mutations in HIV-1 DNA reverse transcriptase sequence during effective ART.

Nouchi A, Nguyen T, Valantin MA, Simon A, Sayon S, Agher R, Calvez V, Katlama C, Marcelin AG, Soulie C.

J Antimicrob Chemother. 2018 Aug 1;73(8):2141-2146. doi: 10.1093/jac/dky130.

PMID:
29846589
29.

Reply to Das and Berkhout, "How Polypurine Tract Changes in the HIV-1 RNA Genome Can Cause Resistance against the Integrase Inhibitor Dolutegravir".

Malet I, Subra F, Richetta C, Charpentier C, Collin G, Descamps D, Calvez V, Marcelin AG, Delelis O.

MBio. 2018 May 29;9(3). pii: e00623-18. doi: 10.1128/mBio.00623-18. No abstract available.

30.

Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies.

Lambert-Niclot S, Grude M, Meynard JL, Marcelin AG, Valantin MA, Flandre P, Izopet J, Moinot L, Bouteloup V, Calvez V, Katlama C, Girard PM, Morand-Joubert L.

Clin Infect Dis. 2018 Nov 28;67(12):1883-1889. doi: 10.1093/cid/ciy382.

PMID:
29767684
31.

Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study).

Lambert-Niclot S, Grude M, Chaix ML, Charpentier C, Reigadas S, Le Guillou-Guillemette H, Rodallec A, Amiel C, Maillard A, Dufayard J, Mourez T, Mirand A, Guinard J, Montes B, Vallet S, Marcelin AG, Descamps D, Flandre P, Delaugerre C, Morand-Joubert L; ANRS AC-11 Resistance Group.

J Antimicrob Chemother. 2018 Aug 1;73(8):2147-2151. doi: 10.1093/jac/dky142.

PMID:
29718247
32.

Bridging β-Cyclodextrin Prevents Self-Inclusion, Promotes Supramolecular Polymerization, and Promotes Cooperative Interaction with Nucleic Acids.

Evenou P, Rossignol J, Pembouong G, Gothland A, Colesnic D, Barbeyron R, Rudiuk S, Marcelin AG, Ménand M, Baigl D, Calvez V, Bouteiller L, Sollogoub M.

Angew Chem Int Ed Engl. 2018 Jun 25;57(26):7753-7758. doi: 10.1002/anie.201802550. Epub 2018 May 25.

PMID:
29693753
33.

Usefulness of Kaposi's Sarcoma-Associated Herpesvirus (KSHV) DNA Viral Load in Whole Blood for Diagnosis and Monitoring of KSHV-Associated Diseases.

Jary A, Leducq V, Palich R, Gothland A, Descamps D, Joly V, Lambert-Niclot S, Amiel C, Canestri A, Mirand A, Gault E, Vabret A, Valantin MA, Katlama C, Calvez V, Dupin N, Spano JP, Marcelin AG.

J Clin Microbiol. 2018 May 25;56(6). pii: e00569-18. doi: 10.1128/JCM.00569-18. Print 2018 Jun. No abstract available.

34.

Dolutegravir resistance mutations: lessons from monotherapy studies.

Blanco JL, Marcelin AG, Katlama C, Martinez E.

Curr Opin Infect Dis. 2018 Jun;31(3):237-245. doi: 10.1097/QCO.0000000000000453. Review.

PMID:
29634660
35.

State of the Art in HIV Drug Resistance: Science and Technology Knowledge Gap.

Boucher CA, Bobkova MR, Geretti AM, Hung CC, Kaiser R, Marcelin AG, Streinu-Cercel A, van Wyk J, Dorr P, Vandamme AM.

AIDS Rev. 2018 Jan-Mar;20(1):27-42. Review.

PMID:
29628515
36.

State of the Art in HIV Drug Resistance: Surveillance and Regional Gaps.

Boucher CA, Bobkova MR, Hung CC, Kaiser R, Marcelin AG, Streinu-Cercel A, van Wyk J, Dorr P, Vandamme AM.

AIDS Rev. 2018 Jan-Mar;20(1):43-57. Review.

PMID:
29628514
37.

Chronic hepatitis E in a heart transplant patient: sofosbuvir and ribavirin regimen not fully effective.

Todesco E, Mazzola A, Akhavan S, Abravanel F, Poynard T, Roque-Afonso AM, Peytavin G, Marcelin AG, Calmus Y, Lecuyer L, Guillemain R, Conti F.

Antivir Ther. 2018;23(5):463-465. doi: 10.3851/IMP3227.

PMID:
29504509
38.

Pathway involving the N155H mutation in HIV-1 integrase leads to dolutegravir resistance.

Malet I, Ambrosio FA, Subra F, Herrmann B, Leh H, Bouger MC, Artese A, Katlama C, Talarico C, Romeo I, Alcaro S, Costa G, Deprez E, Calvez V, Marcelin AG, Delelis O.

J Antimicrob Chemother. 2018 May 1;73(5):1158-1166. doi: 10.1093/jac/dkx529.

PMID:
29373677
39.

Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen.

Charpentier C, Malet I, Andre-Garnier E, Storto A, Bocket L, Amiel C, Morand-Joubert L, Tumiotto C, Nguyen T, Maillard A, Rodallec A, Leoz M, Montes B, Schneider V, Plantier JC, Dina J, Pallier C, Mirand A, Roussel C, Signori-Schmuck A, Raymond S, Calvez V, Delaugerre C, Marcelin AG, Descamps D.

J Antimicrob Chemother. 2018 Apr 1;73(4):1039-1044. doi: 10.1093/jac/dkx511.

PMID:
29342281
40.

Performance of genotypic algorithms for predicting tropism for HIV-1 CRF01_AE recombinant.

Soulie C, Morand-Joubert L, Cottalorda J, Charpentier C, Bellecave P, Le Guen L, Yerly S, Montes B, Fafi-Kremer S, Dina J, Avettand-Fenoel V, Amiel C, Roussel C, Pallier C, Zafilaza K, Sayon S, Signori-Schmuck A, Mirand A, Trabaud MA, Berger S, Calvez V, Marcelin AG; ANRS AC11 resistance group.

J Clin Virol. 2018 Feb - Mar;99-100:57-60. doi: 10.1016/j.jcv.2017.12.014. Epub 2018 Jan 8.

PMID:
29331843
41.

Anaplastic Kaposi's sarcoma: 5 cases of a rare and aggressive type of Kaposi's sarcoma.

Chapalain M, Goldman-Lévy G, Kramkimel N, Carlotti A, Franck N, Lheure C, Audard V, Avril MF, Marcelin AG, Damotte D, Terris B, Aractingi S, Dupin N.

Ann Dermatol Venereol. 2018 Jan;145(1):21-28. doi: 10.1016/j.annder.2017.09.593. Epub 2017 Dec 28.

PMID:
29290414
42.

Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen.

Raymond S, Nicot F, Pallier C, Bellecave P, Maillard A, Trabaud MA, Morand-Joubert L, Rodallec A, Amiel C, Mourez T, Bocket L, Beby-Defaux A, Bouvier-Alias M, Lambert-Niclot S, Charpentier C, Malve B, Mirand A, Dina J, Le Guillou-Guillemette H, Marque-Juillet S, Signori-Schmuck A, Barin F, Si-Mohamed A, Avettand Fenoel V, Roussel C, Calvez V, Saune K, Marcelin AG, Rodriguez C, Descamps D, Izopet J; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) AC11 Resistance Study Group.

Clin Infect Dis. 2018 May 2;66(10):1588-1594. doi: 10.1093/cid/cix1070.

PMID:
29244143
43.

Darunavir/ritonavir monotherapy at a low dose (600/100 mg/day) in HIV-1-infected individuals with suppressed HIV viraemia.

Seang S, Schneider L, Nguyen T, Lê MP, Soulie C, Calin R, Caby F, Valantin MA, Tubiana R, Assoumou L, Marcelin AG, Peytavin G, Katlama C.

J Antimicrob Chemother. 2018 Feb 1;73(2):490-493. doi: 10.1093/jac/dkx417.

PMID:
29216346
44.

Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer.

Guihot A, Marcelin AG, Massiani MA, Samri A, Soulié C, Autran B, Spano JP.

Ann Oncol. 2018 Feb 1;29(2):517-518. doi: 10.1093/annonc/mdx696. No abstract available.

45.

Retention in Care among Patients with Early HIV Disease in Haiti.

Hennessey KA, Leger TD, Rivera VR, Marcelin A, McNairy ML, Guiteau C, Devieux JG, Marcelin Y, Charles B, Cremieux PY, Koenig SP, Pape JW.

J Int Assoc Provid AIDS Care. 2017 Nov/Dec;16(6):523-526. doi: 10.1177/2325957417742670. Epub 2017 Nov 29.

PMID:
29187075
46.

No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir.

Perrier M, Visseaux B, Landman R, Joly V, Todesco E, Yazdanpanah Y, Calvez V, Marcelin AG, Descamps D, Charpentier C.

J Antimicrob Chemother. 2018 Jan 1;73(1):173-176. doi: 10.1093/jac/dkx366.

PMID:
29077926
47.

Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.

Malet I, Subra F, Charpentier C, Collin G, Descamps D, Calvez V, Marcelin AG, Delelis O.

MBio. 2017 Sep 26;8(5). pii: e00922-17. doi: 10.1128/mBio.00922-17.

48.

Multicenter comparison of the new Cobas 6800 system with Cobas Ampliprep/Cobas TaqMan and Abbott RealTime for the quantification of HIV, HBV and HCV viral load.

Wirden M, Larrouy L, Mahjoub N, Todesco E, Damond F, Delagreverie H, Akhavan S, Charpentier C, Chaix ML, Descamps D, Calvez V, Marcelin AG.

J Clin Virol. 2017 Nov;96:49-53. doi: 10.1016/j.jcv.2017.09.007. Epub 2017 Sep 20.

PMID:
28950186
49.

Characterization of a Propionibacterium acnes Surface Protein as a Fibrinogen-Binding Protein.

Grange PA, Raingeaud J, Morelle W, Marcelin AG, Calvez V, Dupin N.

Sci Rep. 2017 Jul 25;7(1):6428. doi: 10.1038/s41598-017-06940-3.

50.

Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France.

Pialoux G, Marcelin AG, Cawston H, Guilmet C, Finkielsztejn L, Laurisse A, Aubin C.

Expert Rev Pharmacoecon Outcomes Res. 2018 Feb;18(1):83-91. doi: 10.1080/14737167.2017.1359542. Epub 2017 Jul 31.

PMID:
28741965

Supplemental Content

Loading ...
Support Center